Loading clinical trials...
Loading clinical trials...
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Forest Laboratories
Collaborators
NCT06894212 · Schizophrenia
NCT06003036 · Schizophrenia, Schizoaffective Disorder
NCT04226898 · Schizophrenia, Schizoaffective Disorder
NCT05240976 · Schizophrenia
NCT05052853 · Prodromal Schizophrenia
Forest Investigative Site 48
Costa Mesa, California
Forest Investigative Site 50
Long Beach, California
Forest Investigative Site 42
Paramount, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions